US FDA requires Lilly to conduct post-marketing studies for obesity pill The U.S. Food and Drug Administration said Eli Lilly is required to conduct post-marketing trials to gauge risks for liver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results